-

The messenger RNA vaccine BNT162b2 (Pfizer–BioNTech) has 95% efficacy against coronavirus disease 2019 (Covid-19). Qatar launched a mass immunization campaign with this vaccine on December 21, 2020. As of March 31, 2021, ...

Correction to: Cancer Cell Int (2020) 20:107 https://doi.org/10.1186/s12935-020-01190-2

Since its emergence in November, 2021, the omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly spread and quickly overtaken the delta (B.1.617.2) variant as the most common cause of infection.1 Due to numerous spike ...

Legionella spp. is transmitted from water to humans by aerosol-generating devices, including cooling towers (CTs). There have not been published reports about Legionella in these systems in Qatar. Ten CTs in Qatar University ...

[No abstract available]

The SARS-CoV-2 pandemic has severely affected international travel. With efficacious COVID-19 vaccines available, Qatar implemented a pilot program between February 18 and April 26, 2021, to ease travel restrictions by ...

More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...

COVID-19 vaccine antigen dose might affect protection against SARS-CoV-2 infection,1, 2 but direct evidence to quantify this effect is absent. We conducted a matched, retrospective, cohort study using a regression ...

Beyond an in vitro setting, the use of a biological system is considered imperious to unravel the enigma of host-pathogen interactions, particularly those eventuating in an infectious disease scenery. In the past two-decades, ...